Genetic screening for GBA1 in Parkinson’s disease patients

Not Applicable

• Conditions: Parkinson's disease, Parkinsonism; Nervous System Diseases

• Registration Number: ISRCTN99451262
• Lead Sponsor: Vanqua Bio Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-11-08
• Last Update Posted: 20 November 2023
• Study Completion: 2024-11-30

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1. Age 40-80
2. All participants must understand and provide written informed consent prior to any study-specific procedures
3. Able to speak, read, and understand study procedures in Dutch sufficiently to allow completion of all study assessments
4. Confirmed clinical diagnosis of Parkinson’s disease by a neurologist within the last 5 years, based on presence of bradykinesia and either resting tremor and/or muscular rigidity in at least one limb
5. Willing to be contacted regarding potential participation in future interventional clinical trials

Exclusion Criteria

1. History of a significant medical or psychiatric comorbidity that would preclude the subject’s participation in an interventional clinical trial
2. Known GBA-1 mutation for Parkinson’s disease

Study & Design

• Study Type: Observational
• Study Design: Not specified